The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy, Published online: 12 February 2019; doi:10.1038/s41568-019-0116-xThis Review discusses recent work demonstrating that immune checkpoint inhibitor efficacy is affected by a combination of factors involving tumour genomics, host germline genetics, programmed cell death 1 ligand 1 (PDL1) levels and other features of the tumour microenvironment, as well as the gut microbiome.
Shaping a Nature Reviews Cancer article
Shaping a <i>Nature Reviews Cancer</i> article, Published online: 08 February 2019; doi:10.1038/s41568-019-0120-1How does a Nature Reviews Cancer Review or Perspectives article move from an idea to a published article? Here, in the spirit of transparency, we provide some insights into this process.
Targeting endovascular progenitors controls cancer
Targeting endovascular progenitors controls cancer, Published online: 07 February 2019; doi:10.1038/s41568-019-0119-7Targeting endovascular progenitors controls cancer
Epigenetic therapy in immune-oncology
Epigenetic therapy in immune-oncology, Published online: 05 February 2019; doi:10.1038/s41568-019-0109-9In this Review, Jones et al. present the evidence that epigenetic therapies can induce the expression of endogenous retroviruses and cancer–testis antigens normally silenced by DNA methylation in most somatic cells. As a consequence, a state of viral mimicry is evoked in cancer cells, leading to an innate immune response. Understanding this process has implications for combination therapy with epigenetic drugs and immunotherapies to improve clinical outcomes for patients with cancer.
Senolytic helpers, Published online: 05 February 2019; doi:10.1038/s41568-019-0115-yRuscetti, Leibold, Bott et al. show that the growth of Kras-mutant lung tumours is sensitive to combined blockade of KRAS effectors. This was dependent on induction of the senescence-activated phenotype in cancer cells, followed by natural killer cell-mediated cell clearance.
Glioblastoma is ‘hot’ for personalized vaccines
Glioblastoma is ‘hot’ for personalized vaccines, Published online: 31 January 2019; doi:10.1038/s41568-019-0118-8Two phase I studies, recently published in Nature, show that the administration of personalized vaccines to newly diagnosed patients with glioblastoma generates tumour-reactive T cells that infiltrate glioblastomas, turning them into ‘hot’ tumours potentially susceptible to further immunotherapy approaches.
Author Correction: Cancer in wildlife: patterns of emergence
Author Correction: Cancer in wildlife: patterns of emergence, Published online: 31 January 2019; doi:10.1038/s41568-019-0113-0Author Correction: Cancer in wildlife: patterns of emergence
Unmasking cancer cell character
Unmasking cancer cell character, Published online: 31 January 2019; doi:10.1038/s41568-019-0117-9Two studies show that cancer cells contain sufficient quantities of immunostimulatory nucleic acids to trigger interferon signalling, increase antitumour immunity and overcome resistance to checkpoint blockade. Loss of the RNA-editing enzyme ADAR1 enables tumour cells to sense these innate ligands.
Methylated clusters, Published online: 31 January 2019; doi:10.1038/s41568-019-0114-zGkountela et al. have identified that circulating tumour cell (CTC) clusters from patients and mouse models with breast cancer have a distinct DNA methylation profile from that of single CTCs, which together with the phenotypic difference represent a targetable therapeutic vulnerability of metastasis.
Author Correction: Every step of the way: integrins in cancer progression and metastasis
Author Correction: Every step of the way: integrins in cancer progression and metastasis, Published online: 31 January 2019; doi:10.1038/s41568-019-0112-1Author Correction: Every step of the way: integrins in cancer progression and metastasis
Immune control by amino acid catabolism during tumorigenesis and therapy
Immune control by amino acid catabolism during tumorigenesis and therapy, Published online: 29 January 2019; doi:10.1038/s41568-019-0106-zThis Review discusses how increased catabolism of the amino acids tryptophan and arginine driven by inflammatory processes in the tumour microenvironment contributes to tumorigenesis, suppression of antitumour immunity and potentially neurological comorbidities associated with cancer.
Trafficking signals for metastasis
Trafficking signals for metastasis, Published online: 29 January 2019; doi:10.1038/s41568-019-0111-2Keklikoglou et al. show that, in mouse models of chemoresistant breast cancer, paclitaxel and doxorubicin trigger the production of tumour-derived extracellular vesicles with pro-metastatic properties that are dependent on annexin A6.
The global cancer burden: necessity is the mother of prevention
The global cancer burden: necessity is the mother of prevention, Published online: 25 January 2019; doi:10.1038/s41568-019-0110-3Cancer brings an increasing health and economic burden worldwide, and the greatest impact is had on the most vulnerable populations. In this Comment, Christopher Wild discusses the need for investment to ensure long-term cancer prevention strategies.
Organoid 2.0, Published online: 22 January 2019; doi:10.1038/s41568-019-0108-xNeal et al. have successfully established patient-derived organoids of tumour epithelia retaining native immune cells, thereby recapitulating tumour microenvironment diversity and enabling immuno-oncology studies.
Rare ribosomopathies: insights into mechanisms of cancer
Rare ribosomopathies: insights into mechanisms of cancer, Published online: 22 January 2019; doi:10.1038/s41568-019-0105-0Rare ribosomopathies: insights into mechanisms of cancer
Publisher Correction: Expanding the search
Publisher Correction: Expanding the search, Published online: 17 January 2019; doi:10.1038/s41568-019-0107-yPublisher Correction: Expanding the search
Fasting in oncology: a word of caution
Fasting in oncology: a word of caution, Published online: 16 January 2019; doi:10.1038/s41568-018-0098-0Fasting in oncology: a word of caution
Reply to ‘Fasting in oncology: a word of caution’
Reply to ‘Fasting in oncology: a word of caution’, Published online: 16 January 2019; doi:10.1038/s41568-018-0100-xReply to ‘Fasting in oncology: a word of caution’
Modelling cancer in microfluidic human organs-on-chips
Modelling cancer in microfluidic human organs-on-chips, Published online: 15 January 2019; doi:10.1038/s41568-018-0104-6In vitro cancer models often fail to faithfully recapitulate the local tissue and organ microenvironment. Organs-on-chips can overcome this limitation and better mimic in vivo cancer phenotypes. This Review outlines the advances that have been made with this technology and explains the challenges that must be overcome to see its implementation into drug development pipelines and clinical cancer care.
Get to know your epigenetic target
Get to know your epigenetic target, Published online: 07 January 2019; doi:10.1038/s41568-018-0103-7Two studies suggest that caution is warranted in attempts to inhibit the histone methyltransferase G9a for cancer therapy, as its loss can promote tumour development and evolution.